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Obesity is characterised by altered gut microbiota, low-grade inﬂammation and increased
endocannabinoid (eCB) system tone; however, a clear connection between gut microbiota and
eCB signalling has yet to be conﬁrmed. Here, we report that gut microbiota modulate the intestinal
eCB system tone, which in turn regulates gut permeability and plasma lipopolysaccharide (LPS)
levels. The impact of the increased plasma LPS levels and eCB system tone found in obesity on
adipose tissue metabolism (e.g. differentiation and lipogenesis) remains unknown. By interfering
with the eCB system using CB1 agonist and antagonist in lean and obese mouse models, we found
that the eCB system controls gut permeability and adipogenesis. We also show that LPS acts as
a master switch to control adipose tissue metabolism both in vivo and ex vivo by blocking
cannabinoid-driven adipogenesis. These data indicate that gut microbiota determine adipose tissue
physiology through LPS-eCB system regulatory loops and may have critical functions in adipose
tissue plasticity during obesity.
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Introduction
Obesity and type II diabetes have reached epidemic propor-
tions. Recent data have shown that these metabolic disorders
are characterised by low-grade inﬂammation of unknown
molecular origin (Hotamisligil and Erbay, 2008; Shoelson
and Goldﬁne, 2009); therefore, it is of the utmost importance
to identify the link between inﬂammation and adipose
tissue metabolism, and plasticity. Emerging data have
implicated gut microbiota (Ley et al, 2005; Turnbaugh et al,
2006; Cani et al, 2007a,b, 2008; Cani and Delzenne, 2009) and
the endocannabinoid (eCB) system (Lambert and Muccioli,
2007; Di Marzo, 2008) as modulators of obesity and energy
homeostasis.
During the past several years, our group and others have
provided evidence that gut microbiota inﬂuence whole-body
metabolism by affecting energy balance (Ley et al, 2005;
Turnbaugh et al, 2006; Claus et al, 2008), gut permeability
(Cani et al, 2008, 2009) and low-grade inﬂammation (Cani
et al, 2007a,b) associated with obesity and related metabolic
disorders. Recently, studies performed in gnotobiotic mice
have emphasised the contributions of gut microbiota to fat
storage (Backhed et al, 2004, 2007; Samuel et al, 2008).
Obesity is characterised by the massive expansion of
adipose tissues and is associated with inﬂammation (Weisberg
et al, 2003). It is possible that both this expansion and the
associated inﬂammation are controlled by microbiota and
lipopolysaccharide (LPS) (Cani et al, 2007a, 2008), a cell wall
component of Gram-negative bacteria that is among the most
potent inducers of inﬂammation. On the other hand, obesity is
alsocharacterisedbygreatereCBsystemtone,thatisincreased
eCB plasma levels, altered expression of the cannabinoid
receptor 1 (CB1 mRNA) and increased eCB levels in adipose
tissues(Engelietal,2005;Bluheretal,2006;Matiasetal,2006;
Cote et al, 2007; D’Eon et al, 2008; Starowicz et al, 2008;
Di Marzo et al, 2009; Izzo et al, 2009). Several studies have
suggested a close relationship between LPS and the eCB
system. LPS controls the synthesis of eCBs both in vivo
(Hoareau et al, 2009) and in vitro (Di Marzo et al, 1999;
Maccarrone et al, 2001) through mechanisms that depend on
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pharmacological impairments of CB1 receptor have been
shown to protect against the development of obesity, steatosis
and related inﬂammation (Osei-Hyiaman et al, 2005, 2008;
Gary-Bobo et al, 2007; DeLeve et al, 2008), the molecular link
between eCB system activation and disorders associated with
obesity remains elusive.
There is accumulating evidence that the eCB system,
inﬂammation and obesity are interconnected (Scherer and
Buettner, 2009); however, the convergent molecular mechan-
isms that may affect adiposity remain to be clariﬁed. Here,
we tested the hypothesis that gut microbiota and the eCB
system control gut permeability and adipogenesis through
an LPS-dependent mechanism under physiological and
obesity-related conditions.
Results
Gut microbiota modulate colon CB1 receptor
mRNA expression in normal and obese mice
To determine the contributions of gut microbiota to the
regulation of the intestinal eCB system in both physiological
and obese conditions, we investigated selective models (e.g.
prebiotictreatment(Canietal,2007b,2009;Martinetal,2008)
and a high-fat diet (HFD) (Cani et al, 2007a, 2008)) and drastic
models (e.g. antibiotic treatment (Seki et al, 2007; Cani et al,
2008; Membrezet al, 2008) and germ-freemice (Backhed et al,
2004)) of gut microbiota modulation, in addition to mice
bearing speciﬁc mutations in Myd88, an important gene
involved in toll-like receptor (TLR)-mediated bacteria–host
interactions. Tissue-speciﬁc changes in colonic CB1 mRNA
expression were observed in all ﬁve models (Figure 1A–C, E,
G), whereas expression in the jejunum was unaffected (Figure
1DandF).Incontrast, alteredcolonic expressionofthesecond
cannabinoid receptor CB2 was not observed in any of the
models tested (Supplementary Figure S1A–D), suggesting
that gut microbiota selectively modulate colonic CB1 mRNA
expression.
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG)
(Devane et al, 1992; Mechoulam et al, 1995) are endogenous
CB1 and CB2 ligands, and the main enzymes responsible for
their degradation are fatty acid amide hydrolase (FAAH)
(Cravatt et al, 1996) and monacylglycerol lipase (MGL) (Dinh
et al, 2002), respectively. Consistent with the tissue-speciﬁc
modulationofCB1mRNAexpression,wefoundthatFAAHand
MGL expression levels were affected by gut microbiota in the
colon (Supplementary Figure S2A, C, D and E), but not in the
jejunum (Supplementary Figure S2B and F). We earlier
showed that gut microbiota, at least in part, contribute to the
systemic and hepatic inﬂammation associated with obesity
(Cani et al, 2008, 2009) by increasing gut permeability,
resulting in elevated LPS levels (deﬁned as metabolic
endotoxaemia). Obesity is also characterised by altered tone
of the intestinal eCB system (Izzo et al, 2009). Thus, we
hypothesised that the eCB system could link the development
of gut permeability to the higher plasma LPS levels associated
with obesity. To support these observations, we measured the
intestinal AEA and 2-AG tissue content in genetically obese
mice (B6.V-Lep
ob/J; ob/ob) and in ob/ob mice fed prebiotics.
Consistent with the decrease in colonic CB1 mRNAexpression,
we found that AEA content was reduced, whereas FAAH
mRNA expression was increased (Figure 2A) in obese mice
fed prebiotics. On the other hand, 2-AG content was not
affected, despite a decrease in MGL mRNA expression
(Figure 2A). Furthermore, these markers were not affected in
thejejunum (Supplementary FigureS3A and B), strengthening
the link between the eCB system (as indicated by CB1
mRNA, FAAH mRNA and AEA levels) and gut microbiota.
Accordingly, we found that the reduced plasma LPS levels in
obesemicefedprebiotics(Figure2B)correlatedwithbothAEA
levels and CB1 mRNA expression in the colon (Pearson’s
correlation between LPS and CB1 mRNAwas r¼0.46, P¼0.04,
whereas the correlation between LPS and AEA was r¼0.43,
P¼0.05).
CB1 receptor controls gut permeability
To clearly show that the eCB system regulates gut barrier
function, we designed two in vivo experiments in obese and
lean mice. In the ﬁrst experiment, we blocked the CB1 receptor
with a speciﬁc, selective antagonist (SR141716A) in obese
ob/ob mice with disrupted gut barrier and metabolic endotox-
aemia (Brun et al, 2007; Cani et al, 2009) (Figure 2C and F;
Ob-CT versus CT, Po0.05). As blocking CB1 receptors also
reducefoodintake,weusedpairfeedingasacontrol.Wefound
that obese mice treated with the CB1 receptor antagonist
(Ob-SR) for 12 days exhibited signiﬁcantly reduced gut
permeability as shown by their reduced plasma LPS levels
(Figure 2C) compared with control (Ob-CT) or pair-fed
(Ob-PF) mice. Moreover, we found that blocking the CB1
receptor reduced plasma LPS levels through a mechanism
linked to the improvement of gut barrier function. This
improvement in gut barrier function was inferred from
changes in the distribution and localisation of tight junction
proteins (zonula occludens-1 (ZO-1) and occludin)
(Figures 2D and 3). Consistent with the plasma LPS levels
and plasma glucose levels, pair feeding did not alter the
distribution of tight junction proteins (Figures 2D and 3;
Supplementary Figure S4). Moreover, the discriminant analy-
sis of gut permeability markers (plasma LPS, ZO-1 and
occludin) shown by the canonical plot in Figure 2E supports
the presence of separate clusters between Ob-SR and the other
two groups (Figure 2E).
In addition, we conﬁrmed the earlier ﬁndings that CB1
receptor blockade signiﬁcantly reduces body weight gain as
compared with saline-treated mice (Supplementary Figure
S4A), whereas pair-fed mice display an intermediate pattern.
Moreover, CB1 receptor antagonist treatment signiﬁcantly
decreased the total adiposity index and blood glucose levels,
whereas no changes were observed after pair feeding
(Supplementary Figure S4B and C). Finally, the reduced gut
permeability was associated with decreased expression of the
hepatic inﬂammatory markers TNF-a, PAI-1 and TLR4 mRNA
(data not shown).
In a second set of experiments performed in lean wild-type
mice, we mimicked the increased eCB system tone observed
during obesity by chronic (4-week) infusion of a cannabinoid
receptor agonist (HU-210) through mini-pumps implanted
subcutaneously (s.c.). We found that cannabinoid agonist
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Furthermore, increased plasma ﬂuorescein isothiocyanate-
dextran levels were observed after oral gavage (Figure 2F
and G). These sets of in vivo experiments strongly suggest that
an overactive eCB system increases gut permeability.
Given that in vivo colonic CB1 mRNA expression was
consistently reduced in gut microbiota models known to
improve gut permeability (Figure 1A, B and E) (Cani et al,
2007b, 2008, 2009) and that mice treated with a CB1 receptor
antagonist exhibited improvedgut permeability (Figures 2C, D
and 3), we hypothesised that the intestinal eCB system
controls gut barrier function through a CB1-dependent
mechanism. Plasma LPS levels, however, have also been
proposedasafactorinvolvedinthedevelopmentofgutbarrier
disruption (Kimura et al, 1997; Sheth et al, 2007). Thus, we
used an in vitro cellular model of the intestinal epithelial
barrier (Caco-2 cell monolayers) to investigate the speciﬁc
functions of the eCB system and LPS in the development of gut
permeability. When both LPS and the cannabinoid receptor
agonist HU-210 were applied simultaneously, decreased
Figure 1 Gut microbiota selectively control colon CB1 mRNA expression. CB1 mRNA levels were selectively altered in the colons of mice according to the gut
microbiota–host interaction model tested. (A) Colon CB1 mRNA levels in ob/ob mice fed a normal chow diet (Ob-CT) or treated with prebiotics (Ob-Pre) for 5 weeks
(n¼10). (B) Colon CB1 mRNA levels in lean wild-type mice (CT) or after antibiotic treatment (Ab) for 2 weeks (n¼8–9). (C) Colon CB1 mRNA levels in germ-free (GF)
mice versus conventionally raised mice (CONV-R) (n¼5). (D) Jejunum CB1 mRNA levels in the same groups of mice described in panels A, B and C. (E) Colon CB1
mRNA levels in mice fed a normal chow diet (CT) or a high-fat diet (HFD) enriched with or without prebiotics (HFD-Pre) for 14 weeks (n¼7–8). (F) Jejunum CB1 mRNA
levelsinCT,HFDandHFD-Premice(n¼7–8).(G)ColonCB1mRNAlevelsinwild-type orMyd88
 / micefedanHFDfor8weeks(n¼5).*Po0.05asdeterminedbya
two-tailed Student’s t-test. Data with different superscript letters were signiﬁcantly different according to post hoc ANOVA one-way statistical analysis.
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ZO-1, was observed (Figure 4A and B). Accordingly, the CB1
receptor antagonist normalised occludin and ZO-1 mRNA
expression (Figure 4A and B) and transepithelial electrical
resistance (TEER) ( 9.8±4.4% of the TEER measured before
treatment and 7.3±5.2% of the TEER measured before
treatment, Po0.01, for LPS-HU and LPS-HU-SR1, respec-
tively). In contrast, the CB2 receptor antagonist SR144528 did
not improve these parameters (Figure 4) (TEER¼ 9.8±4.4%
of that measured before treatment and  9.6±6.9% of that
measured before treatment, P40.05, for LPS-HU and LPS-HU-
SR2, respectively). Taken together, these in vivo and in vitro
experiments support the hypothesis that the eCB system has
an important function in the regulation of gut permeability
through a CB1 receptor-dependent mechanism.
Gut microbiota modulation decreases CB1
expression in adipose tissue and fat mass
and controls adipogenesis
Given that obesity is characterised by the dysregulation of eCB
system tone in adipose tissue (Engeli et al, 2005; Bluher et al,
2006; Matias et al, 2006; Cote et al, 2007; D’Eon et al, 2008;
Starowicz et al, 2008; Di Marzo et al, 2009; Izzo et al, 2009),
we investigated this phenomenon in ob/ob mice compared
withtheirleanlittermates.Inadiposetissuesoftheobesemice,
there was a signiﬁcant increase in the mRNA expression of N-
acylphophatidylethanolamine phospholipase D (NAPE-PLD),
the primaryenzyme involvedin AEA synthesis (Muccioli, 2010),
and CB1, along with reduced mRNAexpression of FAAH (Figure
5A–C). Consistent with these ﬁndings, we found a signiﬁcant
Figure 2 The eCB system controls gut permeability through a CB1 receptor-dependent mechanism. (A) AEA and 2-AG levels (per cent of control values), and FAAH
and MGL mRNA levels in the colons of ob/ob mice fed a normal chow diet (Ob-CT) or treated with prebiotics (Ob-Pre) for 5 weeks (n¼10). (B) Plasma LPS levels in ob/
obmicefedanormalchowdiet(Ob-CT)ortreatedwithprebiotics(Ob-Pre)for5weeks(n¼10).(C)PlasmaLPSlevelsinobeseob/obmicetreatedwithvehicle(Ob-CT),
CB1 receptor antagonist or SR141716A (Ob-SR) (10mg/kg//day) or pair fed (Ob-PF) for 12 days (n¼6). (D) Relative score of tight junction (TJ) changes measured by
immunohistological analysis of ZO-1 and occludin in the same mice as in panel C (n¼6). (E) Canonical plot (biplot) showing the data and multivariate means in two
dimensions that best separate the groups when one takes into account gut permeability markers. (F) Plasma LPS levels and (G) plasma levels of dextran-4000-FITC
(FITC) in lean wild-type mice chronically infused with vehicle (CT) or the cannabinoid receptor agonist HU-210 (HU) (100mg/kg/day) through mini-pumps implanted
subcutaneouslyfor4weeks(n¼7).*Po0.05asdeterminedbyatwo-tailedStudent’st-test.Datawithdifferentsuperscriptlettersweresigniﬁcantlydifferentaccordingto
post hoc ANOVA one-way statistical analysis.
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show for the ﬁrst time that ob/ob mice display altered eCB
system tone in adipose tissues.
Our laboratory and others have earlier shown that gut
microbiota participate in the development of adipose tissue
under both physiological and pathological conditions
(Backhed et al, 2004, 2007; Cani et al, 2007a, 2008, 2009;
Samuel et al, 2008). The molecular events linking the gut
microbiota to adipogenesis, however, remain unidentiﬁed.
Here, we conﬁrm that changing the gut microbiota using
prebiotics decreases fat mass development in obese mice
(Figure 6A). Similar to the effects on colonic CB1 receptor
expression, changes in gut microbiota signiﬁcantly decreased
CB1 mRNA expression in adipose tissues (Figure 6B). Given
the recognised functions of AEA in metabolic processes
controlled by the eCB system (Osei-Hyiaman et al, 2005;
Buettner et al, 2008) and our present ﬁndings, we measured
AEA levels and FAAH mRNA expression in adipose tissue.
Prebiotics strongly decreased AEA levels and tended to
increase FAAH mRNA levels (Figure 6C), further supporting
the link between changes in gut microbiota and modulation of
the eCB system.
Given that CB1 receptor activation is known to increase
lipogenesis-induced lipid accumulation in both liver (Osei-
Hyiaman et al, 2005, 2008) and fat cells (Cota et al, 2003;
Bouaboula et al, 2005; Gary-Bobo et al, 2006; Matias et al,
2006; Bellocchio et al, 2008; Pagano et al, 2008), we
investigated whether reduced AEA levels and CB1 mRNA
expression during adipose tissue development could be linked
to the diminution of adipogenesis and/or lipogenesis. To that
end, we used qRT–PCR to determine the expression levels of
the following adipogenic markers: CCAAT/enhancer-binding
protein-a (C/EBP-a), peroxisome proliferator activated recep-
tor-g (PPAR-g) and adipocyte fatty acid-binding protein
(aP2, also known as FABP4, or AFABP). We also examined
the following lipogenic markers: sterol regulatory element-
binding protein-1c (SREBP-1c), a crucial transcription factor
controlling the transcriptional regulation of both acetyl-
CoA carboxylase (ACC) and fatty acid synthase (FAS)
(Osei-Hyiaman et al, 2005).
Strikingly, we found that the decreased fat mass, reduced
CB1 mRNA expression and reduced AEA levels observed after
the modulation of gut microbiota in obese mice were
associated with increases in markers of adipocyte differentia-
tion (PPAR-g, aP2, C/EBP-a) and lipogenesis (SREBP-1c,
ACC, FAS) (Figure 6D and E). Similar results were obtained
(also in obese mice) by blocking CB1 receptor signalling
(Figure 6F and G).
Under physiological conditions, on the other hand, activa-
tion of the eCB system by a cannabinoid receptor agonist
(HU-210) increased adipogenesis in lean mice. Indeed, we
found that activation of the cannabinoid receptors markedly
increased the expression of genes involved in adipocyte
differentiation (PPAR-g, aP2, C/EBP-a) (Figure 7B) and
lipogenesis (SREBP-1c, ACC, FAS), without affecting CB1
mRNA levels (Figure 7C). Meanwhile, we observed a trend
towards an increase in the adiposity index (Figure 7A). These
effects were associated with smaller adipocyte size and an
Figure 3 CB1 receptor antagonist treatment changes the distribution of tight junction proteins. Representative immunoﬂuorescence staining for occludin and ZO-1 in
obese ob/ob mice treated with vehicle (Ob-CT), CB1 receptor antagonist (SR141716A) (Ob-SR) (10mg/kg/day) or pair fed (Ob-PF) for 12 days (n¼6).
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analysis (Figure 7D). Finally, a heat map proﬁle examination
and dendrogram analysis performed on the basis of adipocyte
differentiation, lipogenesis and adipocyte size clearly showed
two separate clusters between CT mice and those treated with
the cannabinoid receptor agonist (Figure 7E). Consistent with
the results obtained using the cannabinoid receptor agonist,
inhibition of AEA degradation by administration of a potent
FAAH inhibitor, URB597 (Kathuria et al, 2003), signiﬁcantly
increased AEA levels (CT: 100±7.4%; URB597: 117.5±4.9;
Po0.05) and promoted adipogenesis (Supplementary Figure
S6). This observation further supports the putative function of
AEA and FAAH in regulating adipogenesis. These ﬁndings
show that cannabinoid receptor activation induces adipogen-
esis in vivo under physiological conditions, thus conﬁrming
earlier data obtained in vitro (Matias et al, 2006; Pagano et al,
2007; Bellocchio et al, 2008).
Recent studies have proposed that obesity and its associated
inﬂammation dysregulate adipose tissue metabolism by
impairing adipogenesis (Gustafson et al, 2009; Isakson et al,
2009; McLaughlin et al, 2009). This phenomenon is associated
with increased eCB system tone. Understanding the molecular
mechanisms responsible for altered adipogenesis is essential
to avoid the associated metabolic complications. Here, we
show that selective changes in gut microbiota or CB1 receptor
antagonist reduce the inﬂammatory tone in obese mice by
impacting the strength of the gut barrier and plasma LPS
levels. This process may participate in the restoration of
adipogenesis after reducing eCB system tone (e.g. with
prebiotics or CB1 receptor antagonists) in pathological
situations such as obesity.
Stimulation of the eCB system leads to
adipogenesis through an LPS-regulated
mechanism
Ourinvivoexperimentssuggestalinkbetweengutmicrobiota,
gut permeability, LPS, the eCB system and control of
adipogenesis. Indeed, LPS receptor activation has been shown
to decrease adipocyte differentiation and lipogenesis (Chung
et al, 2006; Poulain-Godefroy and Froguel, 2007; Poulain-
Figure 4 The eCB system controls gut permeability through a CB1 receptor-
dependent mechanism in vitro. The impact of the CB1 and CB2 receptors, and
LPS on gut permeability was investigated in an in vitro colonic epithelial
monolayer cell model (Caco-2) by measuring tight junction protein markers
(A) Occludin and (B) ZO-1 mRNA expression levels in colonic cells treated with
vehicle (DMSO) or LPS (200mg/ml) or in combination with the cannabinoid
receptor agonist HU-210 (HU) (1mM), the CB1 receptor antagonist SR141716A
(SR1) (1mM) or the CB2 receptor antagonist SR144528 (SR2) (1mM). The data
represent the mean of three to four different experiments performed in triplicate.
Datawithdifferentsuperscriptlettersweresigniﬁcantlydifferentaccordingtopost
hoc ANOVA one-way statistical analysis.
Figure 5 Obese mice are characterised by higher eCB tone in subcutaneous
adipose tissues. (A) NAPE-PLD (N-acylphosphatidylethanolamine-phospholi-
pase D) mRNA, (B)C B 1 mRNA, (C) FAAH mRNA and (D) AEA levels (per cent
of lean values) in the subcutaneous adipose tissue of lean littermates (Lean-Ob)
and obese ob/ob (Ob-Ob) mice (n¼6). *Po0.05 as determined by a two-tailed
Student’s t-test.
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(Di Marzo et al, 1999; Maccarrone et al, 2001; Liu et al, 2003;
Hoareau et al, 2009). Given that the amount of circulating LPS
is under positive control by CB1 through the regulation of eCB
system tone in the gut and gut permeability, in this case, it is
likely that LPS acts as an additional factor (dependent on the
gut microbiota) in the control of adipogenesis and eCB system
regulation. To evaluate this putative mechanism, we investi-
gated the effects of cannabinoid receptor modulation and the
involvement of LPS in the control of adipocyte differentiation
and lipogenesis in cultured adipose tissue explants. Consistent
with the in vivo data, activation of CB1 receptors increased
adipogenic markers in adipose tissue explants from wild-type
mice(Figure8AandB).Inaccordancewiththehypothesisthat
LPS acts as a regulator of adipose tissue differentiation and
lipogenesis, LPS decreased adipocyte differentiation markers,
buthadonlyaminorimpactonlipogenesismarkers(Figure8A
andB). Furthermore,LPScompletelyabolishedtheadipogenic
effects (e.g. adipocyte differentiation and lipogenesis) of
cannabinoid receptor activation. This latter observation
shows that LPS acts as a master signal in eCB regulation of
adipogenesis. Moreover, CB1 mRNA levels were signiﬁcantly
increased by LPS (Figure 8C), supporting earlier observations
that LPS increases eCB system tone (Di Marzo et al, 1999;
Maccarrone et al, 2001; Liu et al, 2003; Hoareau et al, 2009).
To ascertain whether LPS could interfere with eCB system-
induced activation of adipogenesis (HU) in vivo, we treated
lean wild-type mice with LPS (HU-LPS) under the same
experimental conditions as in Figure 7D. As before, increased
LPS levels caused a decrease in adipogenesis markers
(Figure 8D). Taken together, these data suggest that the eCB
system regulates adipogenesis and that this regulation is
controlled by LPS.
Given that increased LPS levels completely abolished the
adipogenic effects of cannabinoid receptor activation, we
wondered whether LPS could also act as a regulator of the
well-characterised PPAR-g-induced adipogenesis. In fact, LPS
blunted PPAR-g-induced adipogenesis (Figure 8E–G).
Discussion
Obesity is characterised by a massive expansion of adipose
tissues, in addition to metabolic and inﬂammatorycomplications
Figure 6 Changes in gut microbiota decrease adiposity and CB1 mRNA expression, and regulate adipogenesis markers. (A) Adiposity index and (B)C B 1 mRNA
expression levels in the adipose tissue of ob/ob mice fed a normal chow diet (Ob-CT) or treated with prebiotics (Ob-Pre) for 5 weeks (n¼10). (C) White adipose tissue
AEA (per cent of control values) and FAAH mRNA levels were measured in the same group of mice (n¼10). (D) Adipocyte differentiation (PPAR-g, aP2 and C/EBP-a)
and(E)lipogenesis(SREBP-1c,ACCandFAS)mRNAexpressionlevelsintheadiposetissueofthesamegroupofmice(n¼10).(F)Adipocytedifferentiation(PPAR-g,
aP2 and C/EBP-a) mRNA expression levels and (G) lipogenesis (SREBP-1c, ACC and FAS) mRNA expression levels in adipose tissue from obese ob/ob mice treated
with vehicle (Ob-CT) or CB1 receptor antagonist (SR141716A) (Ob-SR) (10mg/kg/day) for 12 days (n¼6). *Po0.05 as determined by a two-tailed Student’s t-test.
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crosstalk between gut microbiota and the regulation of
adipogenesis by the eCB system and provide evidence that
gut microbiota physiologically regulate the activity of the
peripheral eCB system in intestinal and adipose tissue. The
peripheral eCB system, in turn, controls gut barrier function
and adipogenesis.
Obesity is characterised by dysregulated eCB system
tone (Figure 5) (Engeli et al, 2005; Bluher et al, 2006; Matias
et al, 2006; Cote et al, 2007; D’Eon et al, 2008; Starowicz et al,
2008; Di Marzo et al, 2009; Izzo et al, 2009), altered gut
permeability and increased plasma LPS levels (Cani et al,
2008, 2009). Pharmacological blockade of the CB1 receptor
has been shown to reduce obesity associated with inﬂamma-
tion by an unresolved mechanism (Gary-Bobo et al,
2007; Caraceni et al, 2009). In this study, we evaluated the
function of intestinal eCB system activation in the develop-
ment of gut permeability, a major source of metabolic
inﬂammation.
Evidence of a link between gut microbiota
and the eCB system tone
Intestinal eCB system tone variations in response to gut
microbiota modulation were observed in germ-free mice and
in mouse models of bacterial–host interactions in colonic
tissue, but almost no effects were seen in the small intestine.
This reﬂects the higher microbial load found in the colon
(Claus et al, 2008). The speciﬁc changes in gut microbiota or
genetic disruptions of gut bacteria–host interactions selec-
tively decreased CB1 mRNA expression in the colon, without
signiﬁcant modulation of CB2 mRNAexpression. Interestingly,
it has been shown that the administration of a very speciﬁc
strain of bacteria, Lactobacillus acidophilus NCFM, increases
CB2 receptor expression in the colon in mice, whereas four
other bacteria strains (well known as probiotics) belonging to
the Lactobacillus and Biﬁdobacterium genera (L. salivarius
Ls-33, L. paracasei Lpc-37, B. lactis Bi-07 and B. lactis Bi-04)
and two Escherichia coli strains have no effect on CB2 receptor
Figure 7 Stimulation of the eCB system leads to adipogenesis in vivo in lean mice. (A) Adiposity index and (B) adipocyte differentiation (PPAR-g, aP2 and C/EBP-a)
(C) lipogenesis (SREBP-1c, ACC and FAS) and CB1 mRNA expression levels measured in lean wild-type mice chronically infused with vehicle (CT) or cannabinoid
receptor agonist HU-210 (HU) (100mg/kg/day) through mini-pumps implanted subcutaneously for 4 weeks (n¼7). (D) Mean adipocyte surface area (mm
2), adipocyte
size (mm
2) distribution and a representative haematoxylin and eosin-stained adipose tissue section (n¼7) from the same group of mice. *Po0.05 as determined by a
two-tailed Student’s t-test. (E) Heat map proﬁle and dendrogram analysis constructed on the basis of adipocyte differentiation mRNA levels, lipogenesis mRNA levels
and adipocyte size markers.
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lack of effect on CB2 expression observed in our study could
merely be explained by the fact that Rousseaux et al (2007)
used a speciﬁc strain and did not investigate the modulation of
gut microbiota. Given that they did not report effects on
colonic eCB system tone (CB1 and FAAH mRNA), we designed
a similar experiment. Despite at least a 100-fold increase in the
probiotic strains in the caecal content of the mice, we did not
ﬁnd any changes in CB1 or FAAH mRNA expression in the
colon (Supplementary Figure S5A and B). Still, CB2 mRNA
Figure 8 The eCB system directly regulates adipogenesis in cultures of adipose tissue explants, and LPS acts as a master switch both in vitro and in vivo.( A) mRNA
expression levels of the adipocyte differentiation markers PPAR-g, aP2 and C/EBP-a;(B) mRNA expression levels of the lipogenesis markers SREBP-1c and FAS and
(C) mRNA expression levels of CB1 in cultured adipose tissue explants exposed to vehicle (CT), LPS or cannabinoid receptor agonist HU-210 (HU) (100nM) alone or in
combination with LPS (100ng/ml) for 24h. (D) mRNA levels of the adipocyte differentiation markers PPAR-g, aP2 and C/EBP-a and the lipogenesis markers SREBP-
1c, ACC and FAS in lean wild-type mice chronically infused with cannabinoid receptor agonist (HU) (100mg/kg/day) with or without the addition of LPS (HU-LPS)
(300mg/kg/day) through mini-pumps implanted subcutaneously for 4 weeks (n¼7). (E) mRNA levels of an adipocyte differentiation marker (aP2), (F) a lipogenesis
marker (FAS) and (G)C B 1 measured incultured adipose tissueexplants exposed to a PPAR-gagonist (troglitazone, TZD)(10mM) aloneor incombination withLPS for
24h.Thedataarethemeanoffourtoﬁvedifferentdeterminationsfrom25pooledmouseadiposedepots.*Indicates Po0.05forthedrugeffect;#indicatesPo0.05for
the effects of LPS; and þindicates Po0.07 by a two-tailed, Student’s t-test.
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(P¼0.136). Taken together, our data support the hypothesis
that gut microbiota participate in the regulation of the
intestinal eCB system and also provide evidence that
speciﬁc changes in gut microbiota known to reduce obesity
and related metabolic disorders (Cani et al, 2007b, 2008,
2009; Membrez et al, 2008) are sufﬁcient to decrease
peripheral eCB system tone in two models of obesity (genetic
and nutritional).
In this study, we conﬁrmed that changes in gut microbiota
afterprebioticingestionreducegutpermeabilityinobesemice.
Blocking the CB1 receptor in obese mice also ameliorated gut
barrier function as shown by improved distribution and
localisation of tight junction proteins (ZO-1 and occludin).
Importantly, this effect was dependent on CB1 receptor
blockade as pair feeding had no effect. Conﬁrming these
results, CB1 activation increased gut permeability markers
in vivo and in vitro. This demonstration that CB1 receptors
control gut permeability suggests a new eCB system-depen-
dent mechanism in the pathogenesis of obesity-associated
inﬂammation (systemic and hepatic).
Impact of eCB system tone on adipogenesis
in obese and lean mice: the function of LPS
Numerous mechanisms have been suggested to explain the
regulation of physiological and pathological adipose tissue
development. Recently, gut microbiota have been suggested to
modulatetheonset ofobesity (Leyetal,2005; Turnbaugh etal,
2006; Cani et al, 2007a,b, 2008; Cani and Delzenne, 2009) and
contribute to fat storage (Backhed et al, 2004, 2007; Martin
et al, 2007; Samuel et al, 2008). Although it is clear that genetic
or pharmacological blockade of the CB1 cannabinoid receptor
protects against the development of obesity (Osei-Hyiaman
et al, 2005, 2008; Gary-Bobo et al, 2007; DeLeve et al, 2008),
the molecular function of the eCB system in adipose tissue is
still under investigation. Here, we identify several in vivo
mechanisms by which the eCB system controls adipose tissue
development through a putative gut microbiota-to-adipose
tissue regulatory loop. An important result of these studies is
the demonstration that peripheral (e.g. intestine and adipose
tissue) eCB system tone (as indicated by CB1 mRNA, FAAH
mRNA and AEA levels) is under the control of gut microbiota.
We can speculate that the altered proﬁle of gut microbiota
found in obesity (Ley et al, 2006; Cani et al, 2007a,b;
Turnbaugh et al, 2009) is, in part, responsible for increased
eCB system tone.
In conjunction with greater eCB system tone, increased
inﬂammation and plasma LPS levels were observed in obese
mice. In contrast, changes in gut microbiota after prebiotic
feeding or CB1 receptor blockade decreased inﬂammation and
eCB tone. Hence, the greater eCB system tone found in obesity
may participate in the regulation of adipogenesis not only
directly by acting on adipose tissue, but also indirectly by
increasing plasma LPS levels. The latter would consequently
impair adipogenesis and promote inﬂammatory states. In
accordance with this putative regulatory loop, it has been
shown that adipogenesis-related genes are downregulated in the
adipose tissue of obese and type II diabetic individuals (Yang
et al, 2004; Dubois et al, 2006).Furthermore, recentstudies have
shown that the inﬂammatory tone associated with obesity leads
to the dysregulation of adipogenesis (Gustafson et al, 2009;
Isakson et al, 2009; McLaughlin et al, 2009). Here, both speciﬁc
modulation of gut microbiota and CB1 receptor blockade
decreased plasma LPS levels and increased adipocyte differ-
entiation and lipogenesis. One possible explanation for these
surprising data could be as follows: plasma LPS levels might be
under the control of CB1 in the intestine (gut barrier function);
therefore, under particular pathophysiological conditions (e.g.
obesity), this could lead to higher circulating LPS levels.
Furthermore, CB1 receptor blockade might paradoxically in-
crease adipogenesis because of the ability of CB1 antagonist to
reduce gut permeability and counteract the LPS-induced
inhibitory effect on adipocyte differentiation and lipogenesis
(i.e. a disinhibition mechanism). In summary, given that these
treatments reduce gut permeability and, hence, plasma LPS
levels and inﬂammatory tone, we hypothesised that LPS could
act as a regulator in this process. This hypothesis was further
supported in vitro and in vivo by the observation that
cannabinoid-induced adipocyte differentiation and lipogenesis
were directly altered (i.e. reduced) in the presence of physiolo-
gical levels of LPS. Notably, whereas our data provide evidence
that the consequences of obesity and gut microbiota dysregula-
tionongutpermeabilityandmetabolicendotoxaemiaareclearly
mediated by the eCB system, the changes observed in adiposity
are likely the result of two system interactions: an LPS-
dependent pathway and dysregulation of eCB system tone.
On the basis of our results, one might predict that restoring
proper physiological levels of eCB and eCB system tone in
obesity-related pathological situations would reduce gut
permeability, low-grade inﬂammation and fat mass develop-
ment.Still,somestudieshaveshownnochange,anincreaseor
even a decrease in eCB system tone in different adipose depots
(e.g. mesenteric, gonadal and subcutaneous) on the onset of
obesity (Starowicz et al, 2008; Izzo et al, 2009; Sarzani et al,
2009; Bennetzen et al, 2010). These differences might be
explained by the markers measured to evaluate eCB system
tone (e.g. AEA, 2-AG, CB1 mRNA or proteins and FAAH
mRNA) or by differences in the level of inﬂammation (e.g.
systemic LPS levels). In the models tested in the present
manuscript, we found a consistent increase in AEA and CB1
mRNA expression and a decrease in FAAH mRNA expression.
We also performed additional experiments in mice with diet-
induced obesity treated for 3 or 8 weeks and found a two- and
threefold increase, respectively, in CB1 mRNA expression in
subcutaneous adipose depots (PD Cani, 2009, personal
communication). Furthermore, in two separate sets of experi-
ments performed in obese and diabetic db/db mice, we
observed a 2.5-fold increase in CB1 mRNA expression in
subcutaneous adipose tissue and a similar increase in
mesenteric fat. On the other hand, FAAH mRNA levels were
decreased by about 90% (PD Cani, 2009, personal commu-
nication). Therefore, given that in all of these models we
observed both increased inﬂammatory markers and eCB
system tone, it is likely that inﬂammation is responsible for
the discrepancies found in the literature and that this is a
consequence of enhanced LPS levels as shown in this study.
We propose the following model to illustrate how the
eCB system links gut microbiota to adipogenesis (Figure 9).
Endocannabinoid system links gut microbiota to adipogenesis
GG Muccioli et al
10 Molecular Systems Biology 2010 & 2010 EMBO and Macmillan Publishers LimitedActivation of the eCB system in the intestine (e.g. through the
gut microbiota) increases gut permeability, which enhances
plasma LPS levels and exacerbates gut barrier disruption and
peripheral eCB system tone in both the intestine and adipose
tissues. Under the pathological conditions of obesity, the
increased eCB tone and LPS levels participate in the
dysregulation of adipogenesis, perpetuating the initial dis-
equilibrium and leading to a vicious cycle (Figure 9).
In conclusion, we have identiﬁed a new pathophysiological
mechanism linking gut microbiota to the eCB system in
intestinal and adipose tissues with a major function in
controlling adipogenesis. In addition, we provide evidence
that adipogenesis is under the control of an LPS-eCB system
regulatory loop. As obesity is commonly characterised by
increased eCB system tone, higher plasma LPS levels, altered
gut microbiota and impaired adipose tissue metabolism, it is
likely that the increased eCB system tone found in obesity is
caused by a failure or a vicious cycle within the pathways
controlling the eCB system.
Modelling symbiotic systems biology such as gut micro-
biota–host interactions is the next great challenge in biological
modelling, especially when aimed at trying to decipher the
supersystem activities that will be crucial to understand gene–




We used male mice between 6 and 9 weeks of age with genetic
compositions of C57/BL/6J, B6.V-Lep
ob/Jmice (from the Jackson
Laboratory). We also used germ-free Swiss Webster and Myd88
 / /
C57BL/6(bredin Pr. Backhed’s laboratory, UniversityofGothenburg).
Their diets consisted of a standard control diet (CT) (A04, Villemois-
son sur Orge, France), an HFD or a controldiet containing a mixture of
prebiotics such as oligofructose (Pre) (Orafti, Tienen, Belgium) (Cani
et al, 2007b, 2009). All animal use was approved by and performed in
accordance with the local ethics committee. Housing conditions were
as speciﬁed by the Belgian Law of 14 November 1993, regarding the
protection of laboratory animals (agreement no. LA 1230314).
Tissue sampling
Mice were anesthetised using intraperitoneal (i.p.) ketamine and
xylazine at concentrations of 100 and 10mg/kg, respectively, after a
5-h fasting period. Blood samples and tissues were harvested for
further analysis. Mice were killed by cervical dislocation. Epididymal,
subcutaneous and visceral adipose depots were precisely dissected
and weighed. The sum of the weights of these three adipose depots
correspondedtotheadiposityindex.Theintestinalsegments(jejunum
and colon) and adipose tissues were immersed in liquid nitrogen and
stored at  801C for further analysis.
Antibiotic treatment
Miceweretreatedwithampicillin(1g/l;Sigma)andneomycin(0.5g/l;
Sigma) in their drinking water for 2 weeks (Cani et al, 2008).
Surgical procedures for implantation
of the osmotic mini-pumps
Mice were implanted s.c. with an osmotic mini-pump (Alzet 2004,
ALZA) as described earlier (Cani et al, 2006, 2007a).
In vivo pharmacological treatments
Micewere injecteds.c. with HU-210 (100mg/kg/day) (Tocris) using the
osmotic mini-pumps for 4 weeks. The pumps also contained LPS from
E. coli 055B:5 at a concentration of 300mg/kg/day (Sigma) or a control
vehicle (0.1% Tween/saline). Mice were injected i.p. with the CB1
receptor antagonist/inverse agonist SR141716A (10mg/kg/day) or
vehicle for 12 days. Mice were injected i.p. with the fatty acid amid
hydrolase inhibitor URB597 (3mg/kg/day) and killed after 24h.
Intestinal permeability in vivo
Intestinal permeability was measured in mice that had fasted for 6h
and received dextran-4000-FITC (Sigma) by gavage (500mg/kg body
weight, 125mg/ml). Measurements were taken as described earlier
(Cani et al, 2009).
Tight junction proteins (occludin and ZO-1) were assessed by
immunohistochemistry as described earlier (Cani et al, 2009).
All assessments were performed in duplicate in non-serial distant
sections and analysed in a double-blind manner by two different
investigators. Plasma LPS concentrations were determined using a kit
based on a Limulus amaebocyte extract (LAL kit endpoint-QCL1000,
Cambrex BioScience, Walkersville, MD). Determination of the non-
inhibitory reaction and optimised sensitivity and speciﬁcity were
performed as described earlier (Cani et al, 2009). An internal control
for LPS recovery was included in each determination and calculation.
Measurement of AEA and 2-AG tissue levels
Tissues were homogenised in CHCl3 (10ml), and a deuterated
standard (d-AEA and 2-AG; 200pmol) was added. Methanol (5ml)
and H2O (2.5ml) were added, and the lipids were then extracted by
vigorousmixing.Aftercentrifugation,theorganiclayerwasrecovered,
driedunderastreamofN2 andpuriﬁedbysolid-phaseextractionusing
silica, followed by elution with an EtOAc-Acetone (1:1) solution
(Muccioli et al, 2007; Muccioli and Stella, 2008). The resulting lipid
fraction was analysed by HPLC-MS using an LTQ Orbitrap mass
spectrometer (ThermoFisher Scientiﬁc) coupled to an Accela HPLC
Figure 9 eCB system-LPS crosstalk participates in the regulation of
adipogenesis by gut microbiota. Activation of the eCB system in the intestine
(e.g. through gut microbiota) increases gut permeability, which enhances plasma
LPS levels. This exacerbates gut barrier disruption and peripheral eCB system
tone in both the intestine and adipose tissues. Increased fat mass results in
enhanced eCB system tone. LPS inhibits both PPAR-induced and cannabinoid
ligand-induced adipogenesis. Overall, the impairment of these regulatory loops
within colon and adipose tissues found in obesity perpetuates the initial
disequilibrium, leading to a vicious cycle. This cycle maintains the increased gut
permeability, eCB system tone, adipogenesis and fat mass development that
characterise obesity.
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using a C-18 Supelguard pre-column and a Supelcosil LC-18 column
(3mM, 4 150mm) (Sigma-Aldrich). Mobile phases A and B were
composed of MeOH-H2O-acetic acid 75:25:0.1 (v/v/v) and MeOH-
acetic acid 100:0.1 (v/v), respectively. The gradient (0.5ml/min) was
designed as follows: transition from 100% A to 100% B linearly over
15min, followed by 10min at 100% B and subsequent re-equilibration
at 100% A. We performed MS analysis in the positive mode with an
APCIionisationsource.ThecapillaryandAPCIvaporisertemperatures
wereset at250and 4001C, respectively. AEA and 2-AG were quantiﬁed
by isotope dilution using their respective deuterated standards with




Caco-2 cells were grown in ﬂasks containing DMEM supplemented
with foetal bovine serum (10%), L-glutamine (1%) and non-essential
amino acids (1%) at 371C in a 5% CO2 atmosphere. For permeability
testing purposes, the cells were seeded on the upper side of Transwell
inserts (Costar) (1.6 10
5/1.12cm
2) and grown for 21 days using the
same media with the addition of penicillin (100IU/ml), streptomycin
(100mg/ml)andamphotericinB(2.5ml/ml)(Invitrogen).Themediain
the upper and lower compartments were changed every other day. On
day 21, basal TEER was measured using an Endohm
TM tissue
resistance chamber (World Precision Instruments, Sarasota, FL)
connected to a Millicell
s-RES (Millipore, Billerica, MA) ohmmeter
before drugs were added (T¼0h). After a 24-h incubation in the
presence of DMSO or LPS (E. coli 055:B5, 200mg/ml) (Precourt et al,
2009) and drugs (1mM HU-210, SR141716A, or SR144528), TEER was
measured (T¼24h). Cells were recovered using TriPure reagent
(Roche) for subsequent mRNA extraction. The TEER data are
expressed as the per cent change from each individual baseline value.
Probiotic treatment
We orally administered probiotics belonging to the Lactobacillus and
Biﬁdobacterium genera(L. acidophilus NCFMsBiﬁdobacteriumlactis
BI-07; Probactiol Plus, Metagenics, Ostende, Belgium) at doses of
1.2 10
9 colony-forming units (CFU) of each strain per day for 10
consecutive days (n¼10 mice). Saline treatment was used as a control
(n¼10 mice).
Microbial analysis after probiotic treatment
The caecal contents of mice collected post mortem were stored at
 801C.MetagenomicDNAwasextractedfromthecaecalcontentusing
the QIAamp DNA stool mini kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. The primers and probes used to
detect Biﬁdobacterium and L. acidophilus were based on 16S rRNA
gene sequences: F-Biﬁdobacterium spp. TCGCGTCYGGTGTGAAAG,
R-Biﬁdobacterium spp. CCACATCCAGCRTCCAC, F-L. acidophilus CCT
TTCTAAGGAAGCGAAGGATand R-L. acidophilus AATTCTCTTCTCGG
TCGCTCTA. PCR ampliﬁcation was carried out as follows: 10min
at 951C followed by 45 cycles of 3s at 951C, 26s at 581Co r6 0 1C
(L. acidophilus or Biﬁdobacterium, respectively) and 10s at 721C.
Detection was achieved with an STEP one PLUS instrument and
software (Applied Biosystems, Foster City, CA) using MESA FAST
qPCRMasterMixPlusforSYBRAssay(Eurogentec,Verviers,Belgium).
Each assay was performed in duplicate in the same run. The cycle
threshold of each sample was then compared with a standard curve
(performed in triplicate) made by diluting genomic DNA (ﬁvefold
serialdilution)(BCCM/LMG, Ghent,Belgium). Thedataareexpressed
as Log CFU/g of caecal content.
Adipose tissue explant cultures
Subcutaneous adipose depots from 25 mice were precisely dissected,
and all visible vessels, particles and conjunctive tissue were removed.
The fat tissue was then cut with scissors into small pieces (4mm
3),
pooled and placed in Krebs buffer (pH 7.4) containing 2% (wt/vol)
free-fatty acid BSA, penicillin (100IU/ml), streptomycin (100mg/ml)
and amphotericin B (2.5ml/ml) (Invitrogen). A total of 250mg of
adipose tissue was rinsed in phosphate-buffered saline and incubated
in 100-mm Petri dishes containing 10ml MEM with Earle’s salts
(Invitrogen) supplemented with 0.5% free-fatty acid-BSA, penicillin
(100IU/ml), streptomycin (100mg/ml) and amphotericin B (2.5ml/ml)
(Invitrogen). All conditions were repeated in four to ﬁve different
dishes (n¼4–5). The dishes were cultured for 24h at 371C in a 5% CO2
atmosphere. The basal concentration of glucose in fresh media was
5mmol/l, whereas the basal levels of cortisol and insulin were
extremely low (B0.5nmol/l and 3pmol/l, respectively). Different
pharmacological agents were used in various combinations in
accordance with the experimental protocols. LPS (E. coli 055:B5,
100ng/ml) (Sigma), HU-210 (100nM) (Tocris) and troglitazone
(10mM) (Sigma) were diluted in DMSO, which also served as a
control. Cell viability did not change over the courseof the experiment
(data not shown). At the end of the experiment, the adipose material
wasrinsedinphosphate-bufferedsaline,collected,immediatelyfrozen
in liquid nitrogen and stored at  801C until subsequent mRNA
analysis.
RNA preparation and real-time qPCR analysis
Total RNAwas prepared from tissues using TriPure reagent (Roche) as
describedearlier(Caniet al, 2008). cDNAwassynthesisedfrom1mgof
total RNAusing a reverse transcription kit (Promega Corp.). qPCR was
performed with an STEP one PLUS instrument and software (Applied
Biosystems) as described earlier (Cani et al, 2008). Primer sequences
for the targeted mouse genes are shown in Supplementary Table 1.
Statistical analysis
The data are expressed as the mean±s.e.m. Differences between two
groups were assessed using an unpaired, two-tailed Student’s t-test.
Data sets involving more than two groups were assessed by ANOVA
followed by a Bonferroni’s post hoc test. Correlations were analysed
using Pearson’s correlation. Data with different superscript letters
were signiﬁcantly different (Po0.05) according to the post hoc ANOVA
statistical analysis. Data were analysed using GraphPad Prism version
5.00 for Windows (GraphPad Software, San Diego, CA) and JMP 8.0.1
(SAS Campus Drive, Cary, NC). The results were considered
statistically signiﬁcant for Po0.05.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (http://www.nature.com/msb).
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